Intratumoral delivery of IL-12 gene by polyvinyl polymeric vector system to murine renal and colon carcinoma results in potent antitumor immunity

Gene Therapy

Volumn 6, Issue 5, 1999, Pages 833-839

  Mendiratta, S K ^a   Quezada, A ^a   Matar, M ^a   Wang, J ^a   Hebel, H L ^a   Long, S ^a   Nordstrom, J L ^a   Pericle, F ^a  

^a GeneMedicine Inc   (United States)

Author keywords

Cancer; Gene delivery; Gene therapy; IL 12; Immunotherapy

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 12; POLYVINYL DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELLULAR IMMUNITY; CLONING VECTOR; COLON CARCINOMA; FEMALE; GENE TARGETING; KIDNEY CARCINOMA; MOUSE; NATURAL KILLER CELL; NONHUMAN; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR REJECTION;

ANIMALS; CARCINOMA, RENAL CELL; CD8-POSITIVE T-LYMPHOCYTES; COLONIC NEOPLASMS; FEMALE; GENE EXPRESSION; GENE THERAPY; GENETIC VECTORS; IMMUNOTHERAPY, ACTIVE; INJECTIONS, INTRALESIONAL; INTERFERON TYPE II; INTERLEUKIN-12; KIDNEY NEOPLASMS; MICE; MICE, INBRED BALB C; NEOPLASMS, EXPERIMENTAL; TUMOR CELLS, CULTURED;

ANIMALIA; MURINAE;

EID: 0033052989     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300891     Document Type: Article

References (37)

1. Mier JW, Atkins MB. Mechanisms of action and toxicity of immunotherapy with cytokines. Curr Op Oncol 1993; 5: 1067-1072.
2. Brunda MJ et al. Role of interferon-γ in mediating the antitumor efficacy of interleukin-12. J Immunother 1995; 17: 71-77.
3. Nastala CL et al. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 1994; 153: 1697-1706.
4. Rakhmilevich AL et al. Cytokine gene therapy of cancer using gene gun technology: superior antitumor activity of interleukin-12. Hum Gene Ther 1997; 8: 1303-1311.
5. Cavallo F et al. Antitumor efficacy of adenocarcicoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J Natl Cancer Inst 1997; 89: 1049-1058.
6. Trinchieri G. Interleukin-12: a proinflammatory cytokine with immuno-regularory functions that bridge innate resistance and antigen-specific adaptive immunity. Ann Rev Immunol 1995; 13: 251-276.
7. Gately MK et al. Regulation of human lymphocyte proliferation by a heterodimeric cytokine, IL-12 (cytotoxic lymphocyte maturation factor). J Immunol 1991; 147: 874-882.
8. Perussia B et al. Natural killer (NK) cell stimulatory factor or IL-12 has differential effects on the proliferation of TCR-αβ+, TCR-γδ+ T lymphocytes and NK cells. J Immunol 1992; 149: 3495-3502.
9. Robertson MJ et al. Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J Exp Med 1992; 175: 779-788.
10. Kobayashi M et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med 1989; 170: 827-845.
11. Naume B, Gately MK, Espevik TA. Comparative study of IL-12 (cytotoxic lymphocyte maturation factor)-, IL-2, and IL-7-induced effects on immunomagnetically purified CD56+ NK cells. J Immunol 1992; 148: 2429-2436.
12. Gately MK, Wolitzky AG, Quinn PM, Chizzonite R. Regulation of human cytolytic lymphocyte responses by interleukin-12. Cell Immunol 1992; 143: 127-142.
13. Chan SH et al. Induction of interferon gamma production by natural killer cell stimulatory factor: characterization of the responder cells and synergy with other inducers. J Exp Med 1991; 173:869-879.
14. Brunda MJ et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1994; 178: 1223-1230.
15. Tannenbaum CS et al. Cytokine and chemokine expression in tumors of mice receiving systemic therapy with IL-12. J Immunol 1996; 156: 693-699.
16. Angiolillo AL et al. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo. J Exp Med 1995; 182: 155-162.
17. Hsieh CS et al. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 1993; 260: 547-549.
18. Manetti R et al. Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type (Th1)-specific immune responses and inhibits the development of IL-4 producing Th cells. J Exp Med 1993; 177: 1199-1204.
19. Orange JS et al. Mechanism of interleukin 12-mediated toxicities during experimental viral infections: role of tumor necrosis factor and glucocorticoids. J Exp Med 1995; 181: 901-914.
20. Marshall E. Cancer trial of interleukin-12 halted. Science 1995; 268: 1555.
21. Zitvogel L et al. Cancer immunotherapy of established tumors with IL-12: effective delivery by genetically engineered fibroblasts. J Immunol 1995; 155: 1393-1403.
22. Tahara H et al. Fibroblasts genetically engineered to secrete interleukin 12 can suppress tumor growth and induce antitumor immunity to a murine melanoma in vivo. Cancer Res 1994; 54: 182-189.
23. Tahara H et al. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol 1995; 154: 6466-6474.
24. Zitvogel L et al. Construction and characterization of retroviral vectors expressing biologically active human interleukin-12. Hum Gene Ther 1994; 5: 1493-1506.
25. Meko JB, Yim JH, Tsung K, Norton JA. High cytokine production and effective antitumor activity of a recombinant vaccinia virus encoding murine interleukin 12. Cancer Res 1995; 55: 4765-4770.
26. Bramson JL et al. Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. Hum Gene Ther 1996; 7: 1995-2002.
27. Mumper RJ et al. Polyvinyl derivatives as novel interactive polymers controlled gene delivery to muscle. Pharmac Res 1996; 5: 701-709.
28. Alila H et al. Expression of biologically active human insulin-like growth factor-I following intramuscular injection of a formulated plasmid in rats. Hum Gene Ther 1997; 8: 1785-1795.
29. Anwer K et al. Systemic effect of human growth hormone after intramuscular injection of a single dose of a muscle-specific gene medicine. Hum Gene Ther 1998; 9: 659-670.
30. Rosa FM, Cochet MM, Fellous M. Interferon and major histocompatibility complex genes: a model to analyse eukaryotic gene regulation? Interferon 1986; 7: 48-87.
31. Tare NS, et al. Administration of recombinant interleukin-12 to mice suppresses hematopoiesis in the bone marrow but enhances hematopoiesis in the spleen. J Interfer Cytok Res 1995; 15: 377-383.
32. Fujiwara H, Hamoaka T. Antitumor and antimetastatic effects of interleukin 12. Cancer Chemother Pharmacol 1996; 38 (Suppl.): S22-S26.
33. Ridge JP, Rosa FD, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 1998; 393: 474-478.
34. Freimark BD et al. Cationic lipids enhance cytokine and cell influx levels in the lung following administration of plasmid: cationic lipid complexes. J Immunol 1998; 160: 4580-4586.
35. Martinotti A et al. CD4 T cells inhibit in vivo the CD8-mediated immune response against murine colon carcinoma cells transduced with interleukin-12 genes. Eur J Immunol 1995; 25: 137-146.
36. Colombo MP et al. Amount of interleukin 12 available at the tumor site is critical for tumor regression. Cancer Res 1996; 56: 2531-2534.
37. Blezinger P et al. Intra-tracheal administration of IL-12 plasmid/cationic lipid complexes inhibits murine lung metastases. Hum Gene Ther (in press).